These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 18804806)

  • 21. Targeting prostate cancer for focal destruction: can we find it?
    Taneja SS; Tareen B
    Cancer; 2008 Oct; 113(7):1500-1. PubMed ID: 18726950
    [No Abstract]   [Full Text] [Related]  

  • 22. Proprostate-specific antigen: its usefulness in the era of multiple-core prostate biopsy.
    Miyakubo M; Ito K; Yamamoto T; Takechi H; Ohi M; Suzuki K
    Int J Urol; 2009 Jun; 16(6):561-5. PubMed ID: 19456991
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intensifying the saturation biopsy technique for detecting prostate cancer after previous negative biopsies: a step in the wrong direction.
    Bott S; Langley S; Hindley R; Montgomery B
    BJU Int; 2009 Mar; 103(5):701. PubMed ID: 19226428
    [No Abstract]   [Full Text] [Related]  

  • 24. Extensive biopsies and transurethral prostate resection in men with previous negative biopsies and high or increasing prostate specific antigen.
    Ploussard G; Dubosq F; Boublil V; Allory Y; de la Taille A; Vordos D; Hoznek A; Abbou CC; Salomon L
    J Urol; 2009 Oct; 182(4):1342-9. PubMed ID: 19683310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fraction of positive cores in prostate needle biopsy is significantly predictive of pathological stage in radical prostatectomy.
    Brimo F; Vollmer RT; Bismar TA
    Histopathology; 2009 Feb; 54(3):374-5. PubMed ID: 19236514
    [No Abstract]   [Full Text] [Related]  

  • 26. Partin tables: past and present.
    Khan MA; Partin AW
    BJU Int; 2003 Jul; 92(1):7-11. PubMed ID: 12823374
    [No Abstract]   [Full Text] [Related]  

  • 27. Re: Renal mass biopsy--a renaissance? B. R. Lane, M. K. Samplaski, B. R. Herts, M. Zhou, A. C. Novick and S. C. Campbell J Urol 2008; 179: 20-27.
    Park BK
    J Urol; 2009 May; 181(5):2386. PubMed ID: 19303098
    [No Abstract]   [Full Text] [Related]  

  • 28. Investigation of human anti-mouse antibodies as potential cause of postprostatectomy PSA elevation.
    Loeb S; Schaeffer EM; Chan DW; Carter HB; Walsh PC; Sokoll LJ
    Urology; 2009 May; 73(5):947-9. PubMed ID: 19394489
    [No Abstract]   [Full Text] [Related]  

  • 29. Re: Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor: B. I. Rini, L. Fong, v. Weinberg, B. Kavanaugh and E. J. Small. J Urol 2006; 175: 2087-2091.
    Brú A
    J Urol; 2007 Apr; 177(4):1585; author reply 1585-6. PubMed ID: 17382784
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparison of 6- and 12-core prostate biopsy in Taiwanese men: impact of total prostate-specific antigen, prostate-specific antigen density and prostate volume on prostate cancer detection.
    Chiang IN; Chang SJ; Pu YS; Huang KH; Yu HJ; Huang CY
    Urol Int; 2009; 82(3):270-5. PubMed ID: 19440012
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Re: Best practice statement on cryosurgery for the treatment of localized prostate cancer R. J. Babaian, B. Donnelly, D. Bahn, J. G. Baust, M. Dineen, D. Ellis, A. Katz, L. Pisters, D. Rukstalis, K. Shinohara and J. B. Thrasher J Urol 2008; 180: 1993-2004.
    Gans W
    J Urol; 2009 May; 181(5):2388. PubMed ID: 19303086
    [No Abstract]   [Full Text] [Related]  

  • 32. Pretreatment prostate-specific antigen velocity and the risk of death from prostate cancer in the individual with low-risk prostate cancer.
    D'Amico AV; Chen MH
    J Clin Oncol; 2009 Aug; 27(22):3575-6. PubMed ID: 19506151
    [No Abstract]   [Full Text] [Related]  

  • 33. Editorial comment on: Analysis of T1c prostate cancers treated at very low prostate-specific antigen levels.
    Eggener S
    Eur Urol; 2009 Mar; 55(3):616. PubMed ID: 18639973
    [No Abstract]   [Full Text] [Related]  

  • 34. Re: The incidence of fluoroquinolone resistant infections after prostate biopsy--are fluoroquinolones still effective prophylaxis? J. Feliciano, E. Teper, M. Ferrandino, R. J. Macchia, W. Blank, I. Grunberger and I. Colon J Urol 2008; 179: 952-955.
    Ng CF; Chan SY
    J Urol; 2008 Oct; 180(4):1570-1; author reply 1571. PubMed ID: 18718610
    [No Abstract]   [Full Text] [Related]  

  • 35. Improving cancer detection by prostate biopsy: the role of core number and site.
    Shinohara K
    Nat Clin Pract Urol; 2006 Oct; 3(10):526-7. PubMed ID: 17031375
    [No Abstract]   [Full Text] [Related]  

  • 36. Re: Risk of prostate cancer after diagnosis of atypical glands suspicious for carcinoma on saturation and traditional biopsies: R. Abouassaly, N. Tan, A. Moussa and J. S. Jones J Urol 2008; 180: 911-914.
    Feldstein MS; Hentz JG
    J Urol; 2009 Apr; 181(4):1960-1; author reply 1961. PubMed ID: 19251278
    [No Abstract]   [Full Text] [Related]  

  • 37. The role of magnetic resonance imaging in targeting prostate cancer in patients with previous negative biopsies and elevated prostate-specific antigen levels.
    Lawrentschuk N; Fleshner N
    BJU Int; 2009 Mar; 103(6):730-3. PubMed ID: 19154475
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Re: Influence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer: M. J. Zelefsky, V. E. Reuter, Z. Fuks, P. Scardino and A. Shippy. J Urol 2008; 179: 1368-1373.
    Coquard R
    J Urol; 2008 Nov; 180(5):2258; author reply 2258. PubMed ID: 18804799
    [No Abstract]   [Full Text] [Related]  

  • 39. Editorial comment on: Post-treatment prostate biopsies in the era of three-dimensional conformal radiotherapy: what can they teach us?
    Stanislaus P; Seitz M
    Eur Urol; 2009 Apr; 55(4):909-10. PubMed ID: 18485577
    [No Abstract]   [Full Text] [Related]  

  • 40. Re: Felix K.-H. Chun, Markus Graefen, Alberto Briganti, Andrea Gallina, Julia Hopp, Michael W. Kattan, Hartwig Huland and Pierre I. Karakiewicz. Initial biopsy outcome prediction--head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. Eur Urol 2007;51:1236-43.
    Stephan C; Meyer HA; Cammann H; Lein M; Loening SA; Jung K
    Eur Urol; 2007 May; 51(5):1446-7; author reply 1448. PubMed ID: 17141943
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.